Study at a glance
How can tissues activate vitamin D locally?
This review combines genetic disorders, mouse experiments and cell studies to explain local vitamin D activation. An enzyme called CYP27B1 changes 25-hydroxyvitamin D into active vitamin D. The kidneys are the main controlled source of active vitamin D in the blood, but other tissues can make it locally. The same enzyme can have different controls in different tissues.
How do different tissues control vitamin D activation?
In the kidneys, vitamin D activation responds to hormones involved in calcium and phosphate balance. Immune and skin cells can respond instead to local signals involved in inflammation and immune activity. Studies of DNA regions that control genes help explain why the same gene can respond differently in different cells. Local effects also depend on access to the starting vitamin D compound, the cell’s ability to receive the signal and the breakdown of vitamin D compounds.
What happens when vitamin D activation is disrupted?
Severe inherited loss of CYP27B1 causes a form of rickets, supporting its importance for normal activation. In certain inflammatory diseases, poorly controlled production outside the kidneys can contribute to high blood calcium. One unusual mouse experiment nevertheless produced active vitamin D after CYP27B1 was removed and very large amounts of the starting compound were supplied. No alternative enzyme was identified, so the finding leaves uncertainty about exceptional conditions.
What can local vitamin D activation studies tell us?
Finding an enzyme does not prove that much local activation is happening or that it adds greatly to blood levels. Active vitamin D made locally may act inside the cell that produces it or on nearby cells. It does not always stay within one cell. Overproduction during disease does not describe how the body normally works. Controls found in one type of immune cell cannot simply be assumed to apply to every tissue.
Read the full article below ↓Local vitamin D metabolism becomes possible when a cell can convert 25-hydroxyvitamin D [25(OH)D] to 1,25-dihydroxyvitamin D [1,25(OH)2D] within its own tissue environment. Bikle’s review is useful because it does not treat CYP27B1 as a kidney-only enzyme or assume that every extrarenal cell runs a miniature version of renal endocrine physiology. The same CYP27B1 sequence is used in kidney and nonrenal tissues, but the regulatory context differs sharply. That distinction is the basis for understanding local autocrine, paracrine and intracrine vitamin D control without overstating how much each tissue contributes to circulating hormone.
The source is a mini-review rather than a single experiment, so its evidential structure is a synthesis of human genetic disease, cell and tissue regulation, immune signalling, mouse genetics and chromatin-based regulatory studies. For this subject, the deepest material lies in the CYP27B1 section and in the later discussion of cell-specific enhancer architecture. Other sections of the review address 25-hydroxylation, VDR biology, vitamin D sufficiency and clinical trials; those are relevant to the broader paper but are not expanded here unless they materially clarify local CYP27B1 control.
CYP27B1 performs the defining local activation reaction
CYP27B1 is the established mitochondrial 25OHD-1α-hydroxylase. It converts 25(OH)D to 1,25(OH)2D, the high-affinity ligand for the vitamin D receptor (VDR). The kidney is the principal regulated source of circulating 1,25(OH)2D, but CYP27B1 expression is also found in epidermis and other epithelia, bone, placenta and immune cells. In those nonrenal sites, locally produced 1,25(OH)2D is positioned to act within the tissue rather than necessarily becoming a major endocrine contribution to the circulation.
This distinction prevents two opposite errors. It is too narrow to describe active vitamin D as something made only in kidney and then delivered unchanged to passive target tissues. But it is equally unsupported to infer that every CYP27B1-positive tissue produces enough 1,25(OH)2D to influence blood concentrations substantially. The presence of the enzyme establishes capacity; physiological importance depends on substrate access, regulatory state, cell abundance and catabolic balance.
Renal regulation is an endocrine programme
Renal CYP27B1 is regulated primarily within mineral homeostasis. Parathyroid hormone stimulates the enzyme, while fibroblast growth factor 23 (FGF23) and 1,25(OH)2D itself suppress it. These inputs allow renal production of circulating active hormone to respond to calcium-phosphate requirements and to its own product. The kidney therefore embeds CYP27B1 within a classic endocrine feedback system.
That feedback architecture is not merely a list of hormones. It defines the physiological job of renal CYP27B1: maintaining systemic active-hormone availability under mineral-regulating control. When local tissue CYP27B1 behaves differently, the difference is not evidence that the enzyme reaction has changed. It reflects a different regulatory system surrounding the same catalytic step.
Immune and epithelial cells use different regulatory inputs
Bikle describes cytokine-responsive CYP27B1 regulation in keratinocytes and macrophages. Interferon-γ, TNFα and TGFβ1 can induce CYP27B1 in these nonrenal settings, whereas dexamethasone is suppressive at least in macrophages. Keratinocytes also distinguish between innate immune signals: activation of TLR2 induces CYP27B1, while TLR4 stimulation by lipopolysaccharide does not in the cited work. Peripheral blood mononuclear cells add another pattern, with IL-1, IL-2 and IL-15 stimulating CYP27B1 activity and IL-4 suppressing it.
These contrasts establish that “extrarenal regulation” is not one programme. Even within immune and epithelial systems, the response depends on cell type and signal. The relevant scientific conclusion is therefore tissue: and context-specific regulation rather than a simple renal-versus-extrarenal binary.
Local regulation can become systemically visible in disease
The physiological consequence of weaker renal-style feedback is most obvious in granulomatous disease and some lymphomas. Cytokine-driven extrarenal CYP27B1 can continue producing 1,25(OH)2D despite circulating conditions that would restrain renal production. When enough activated cells are present, local synthesis can spill beyond a local autocrine or paracrine role and contribute to systemic hypercalcaemia.
This disease example is important because it demonstrates both the power and the boundary of local activation. It proves that extrarenal production can be quantitatively important under particular pathological conditions. It does not establish that normal extrarenal tissues routinely contribute a comparable fraction of circulating 1,25(OH)2D.
Human CYP27B1 loss-of-function establishes causal necessity
Human loss-of-function mutations in CYP27B1 cause vitamin D-dependent rickets type 1A. Affected individuals typically have normal or high 25(OH)D but low, though not always completely absent, 1,25(OH)2D. This phenotype separates precursor availability from activation capacity: adequate substrate cannot compensate for severe failure of the defining 1α-hydroxylation step under ordinary physiology.
The genetic evidence is stronger than an association between enzyme expression and a downstream phenotype. A defined defect in the enzyme produces the predicted biochemical failure and disease. It therefore provides causal support for CYP27B1’s central physiological role while leaving open how much different tissues contribute under normal conditions.
A Cyp27b1-null anomaly prevents an absolute exclusivity claim
The review retains an important experimental anomaly. Mice with global Cyp27b1 deletion were reported to achieve normal 1,25(OH)2D concentrations when given very large amounts of 25(OH)D. The observation suggests that another enzyme may acquire 1α-hydroxylating activity when substrate is driven to unusual levels, although no alternative physiological 1α-hydroxylase had been identified.
This result does not weaken CYP27B1’s established dominant role. Human VDDR1A and ordinary physiology still identify CYP27B1 as the defining activation enzyme. What the anomaly changes is the permissible wording: “CYP27B1 is physiologically central” is supported; “no other enzymatic route can ever generate 1,25(OH)2D under any experimental condition” is too absolute.
Chromatin architecture explains how the same gene acquires tissue-specific control
Bikle later returns to CYP27B1 while discussing genomic regulation. Renal and extrarenal CYP27B1 have the same sequence, so tissue differences must arise from how regulatory factors gain access to the gene. The review describes multicomponent regulatory regions and chromatin organisation as the mechanism that allows endocrine signals to control renal Cyp27b1 without imposing the same programme on nonrenal cells.
A particularly informative line of evidence comes from work identifying a kidney-specific enhancer module. Investigators deleted this module to create a kidney-specific Cyp27b1 “pseudo-null” mouse. The conceptual strength of this model is that it separates renal endocrine regulation from the existence of Cyp27b1 elsewhere: disrupting the renal regulatory architecture can disable kidney-specific endocrine production without requiring deletion of the entire gene from every tissue.
The source also notes a parallel chromatin-based distinction for Cyp24a1 in kidney and nonrenal target tissues. That matters to local control because activation and catabolism are coordinated at the tissue level. Cell-specific enhancer access therefore helps explain why the same vitamin D enzymes can participate in different physiological programmes depending on location.
Substrate availability limits what local CYP27B1 can do
Expression and regulation of CYP27B1 are only part of intracrine capacity. A cell must also obtain 25(OH)D. DBP concentration, DBP binding, free 25(OH)D and receptor-mediated uptake can therefore alter the amount of substrate available for local conversion. This creates a direct connection between cellular uptake and local activation: the same CYP27B1 expression can produce different intracellular outcomes if substrate access differs.
This is also why total circulating 25(OH)D cannot be treated as a complete description of local vitamin D signalling. A blood measurement integrates transport and whole-body status, whereas intracellular exposure additionally depends on local entry, CYP27B1 regulation, VDR availability and catabolic enzymes.
Local activation is balanced by local catabolism
Bikle’s metabolism section places CYP24A1 and CYP3A alongside CYP27B1. CYP24A1 is the dominant 23/24-hydroxylase in many tissues and is induced by 1,25(OH)2D. CYP3A4 can also metabolise both 25(OH)D and 1,25(OH)2D in liver and intestine. Local production of active hormone therefore occurs within a system that can also remove precursor and active ligand.
The presence of catabolic capacity changes the meaning of CYP27B1 expression. A cell with high activation but equally strong feedback-linked catabolism may experience a different duration of active ligand from a cell with the same CYP27B1 but weaker degradation. Intracrine control is therefore a balance of substrate access, activation, receptor signalling and termination rather than an isolated enzyme switch.
What the source does and does not establish
The source most strongly supports a layered model. Kidney CYP27B1 is central to endocrine 1,25(OH)2D production and is regulated by PTH, FGF23 and product feedback. Multiple extrarenal tissues express the same enzyme, but local immune, inflammatory and tissue-specific regulatory signals can govern it differently. Human mutations show causal necessity for ordinary activation, while the high-substrate Cyp27b1-null mouse finding warns against absolute enzymatic exclusivity. Chromatin and enhancer studies explain how one gene can support different regulatory programmes in different tissues.
The evidence does not justify calling all extrarenal CYP27B1 activity purely intracrine; locally produced hormone can act autocrine or paracrine and, in disease, can enter the circulation. It does not prove quantitatively important local activation in every tissue where CYP27B1 mRNA or protein is detected. It also does not support transferring macrophage cytokine regulation wholesale to placenta, bone, parathyroid or other sites. The strongest conclusion is that local vitamin D activation is real, but its magnitude, signals and physiological meaning are determined by tissue context.
This local-activation evidence develops the intracellular conversion stage of Vitamin D Metabolism at the Cellular Level. The catalytic pair is placed in context by Vitamin D Enzyme Pathways (CYP27B1 / CYP24A1), while Vitamin D Clearance and Degradation explains how locally generated active hormone is subsequently constrained.
Primary source
Bikle DD. Vitamin D: Newer Concepts of Its Metabolism and Function at the Basic and Clinical Level. Journal of the Endocrine Society. 2020;4(2):bvz038. Read the full paper.
The Study Summary provides a shorter route through the renal-versus-local control distinction and its strongest mechanistic evidence.
Related reading
Coactivator-independent vitamin D receptor signaling causes severe rickets in mice, that is not prevented by a diet high in calcium, phosphate, and lactose
The vitamin D receptor (VDR) plays a critical role in the regulation of mineral and bone homeostasis.
Original paper ↗Read more →Loss of 24-hydroxylated catabolism increases calcitriol and fibroblast growth factor 23 and alters calcium and phosphate metabolism in fetal mice
The null fetuses were hypercalcemic, modestly hypophosphatemic (compared to Cyp24a1+/− fetuses only), with 3.5-fold increased calcitriol, 4-fold increased fibroblast growth factor 23 (FGF23), and unchanged parathyroid hormone.
Original paper ↗Read more →Target Values for 25-Hydroxy and 1,25-Dihydroxy Vitamin D Based on Their Associations with Inflammation and Calcium-Phosphate Metabolism
Target values for 25-hydroxy vitamin D and 1,25(OH)2D or 1,25-dihydroxy vitamin D remain a topic of debate among clinicians.
Original paper ↗Read more →Intracrine conversion and local control of vitamin D metabolism: Study Summary
A concise study summary of intracrine vitamin D metabolism, local calcitriol production, CYP27B1 activity and tissue-specific control mechanisms.
Read more →Deregulated Renal Calcium and Phosphate Transport during Experimental Kidney Failure
Impaired mineral homeostasis and inflammation are hallmarks of chronic kidney disease (CKD), yet the underlying mechanisms of electrolyte regulation during CKD are still unclear.
Original paper ↗Read more →Dietary phosphorus source reprograms the kidney-intestine axis to dictate calcium-phosphorus efficiency and egg production in aging hens
The decline in egg production in aging hens poses a significant challenge to sustainable poultry production.
Original paper ↗Read more →Effect of nutritional calcium and phosphate loading on calciprotein particle kinetics in adults with normal and impaired kidney function
Plasma approaches metastability with respect to its calcium and phosphate content, with only minor perturbations in ionic activity needed to sustain crystal growth once nucleated.
Original paper ↗Read more →Effects of Different Dietary Interventions on Calcitriol, Parathyroid Hormone, Calcium, and Phosphorus: Results from the DASH Trial
This secondary analysis of the DASH trial aimed to determine the effect of dietary patterns on blood concentrations of calcitriol, parathyroid hormone (PTH), ionized calcium, and urinary excretion of calcium and phosphorus.
Original paper ↗Read more →Fibroblast growth factor-23 and calcium phosphate product in young chronic kidney disease patients: a cross-sectional study
We aimed to describe the effect of the calcium phosphate product (Ca*P) on FGF-23 concentrations in children and young adults without confounding cardiovascular disease.
Original paper ↗Read more →Hereditary 1,25-dihydroxyvitamin D-resistant rickets (HVDRR) caused by a VDR mutation: A novel mechanism of dominant inheritance
In this report, we aimed to confirm whether HVDRR is occasionally inherited as a dominant trait.
Original paper ↗Read more →High-phytate/low-calcium diet is a risk factor for crystal nephropathies, renal phosphate wasting, and bone loss
Phosphate overload contributes to mineral bone disorders that are associated with crystal nephropathies.
Original paper ↗Read more →Klotho in the kidney distal convolution regulates urinary Klotho excretion and kidney calcium reabsorption, but not phosphate homeostasis
Klotho acts as a coreceptor for the phosphaturic hormone fibroblast growth factor-23 (FGF-23) and exists in both a membrane-bound and a soluble form (sKlotho) found in blood and urine.
Original paper ↗Read more →Modulation of renal inflammation and tubular injury by calcitriol in patients with early diabetic kidney disease: a randomized controlled trial
This double-blind, randomized controlled trial investigated the effects of calcitriol supplementation on kidney injury biomarkers in patients with early DKD.
Original paper ↗Read more →Positive association between serum calcium-phosphorus ratio and kidney stone prevalence: Analysis of NHANES data (2007 to 2020)
This study utilized data from the 2007 to 2020 National Health and Nutrition Examination Survey (NHANES), including a total of 34,122 participants.
Original paper ↗Read more →The age-related changes of dietary phosphate responsiveness in plasma 1,25-dihydroxyvitamin D levels and renal Cyp27b1 and Cyp24a1 gene expression is associated with renal α-Klotho gene expression in mice
We found that 1,25-dihydroxyvitamin D levels in plasma were significantly lower in the high phosphate group than the low phosphate group for 1 and 2 month-old mice, but not 13 month-old mice.
Original paper ↗Read more →The dietary management of calcium and phosphate in children with CKD stages 2-5 and on dialysis: clinical practice recommendation from the Pediatric Renal Nutrition Taskforce
Complications of mineral bone disease (MBD) are common and contribute to the high morbidity and mortality seen in children with CKD.
Original paper ↗Read more →The High Calcium, High Phosphorus Rescue Diet Is Not Suitable to Prevent Secondary Hyperparathyroidism in Vitamin D Receptor Deficient Mice
In a second study, we aimed to study whether RD with additional 1 and 2% calcium (in total 3 and 4% of the diet) is able to prevent secondary hyperparathyroidism in the VDR KO mice.
Original paper ↗Read more →Urinary phosphate-containing nanoparticle contributes to inflammation and kidney injury in a salt-sensitive hypertension rat model
Although disturbed phosphate metabolism frequently accompanies chronic kidney disease (CKD), its causal role in CKD progression remains unclear.
Original paper ↗Read more →Association of 25(OH)D status with calcium metabolism, inflammation, and thyroid autoimmunity in patients with type 2 diabetes mellitus
This study aimed to investigate the clinical associations of serum 25(OH)D levels with calcium metabolism, inflammation, thyroid function, and autoimmunity in patients with T2DM.
Original paper ↗Read more →Calcifediol (25-hydroxyvitamin D) improvement and calcium-phosphate metabolism of alendronate sodium/vitamin D3 combination in Chinese women with postmenopausal osteoporosis: a post hoc efficacy analysis and safety reappraisal
The present study aimed to investigate 25-hydroxyvitamin D [25(OH) D] improvement and calcium-phosphate metabolism in Chinese PMO patients treated with 70 mg of alendronate sodium and 5600 IU of vitamin D3 (ALN/D5600).
Original paper ↗Read more →Vitamin D Genetics Beyond Serum 25(OH)D: VDR rs2228570 (FokI) Polymorphism, Inflammation, and Quality of Life in Orthopedic Patients
This study investigated the rs2228570 (FokI) variant in relation to inflammatory, hematologic, and patient-reported outcomes in orthopedic patients.
Original paper ↗Read more →Original sources
Vitamin D: Newer Concepts of Its Metabolism and Function at the Basic and Clinical Level
The interest in vitamin D continues unabated with thousands of publications contributing to a vast and growing literature each year.
Publication details
Bikle DD. Vitamin D: Newer Concepts of Its Metabolism and Function at the Basic and Clinical Level. Journal of the Endocrine Society. 2020;4(2):bvz038. Read the full paper.